AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent HighlightsBusiness Wire • 03/29/23
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/09/22
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung DiseaseGlobeNewsWire • 10/06/22
AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 08/29/22
AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/11/22
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung DiseaseGlobeNewsWire • 06/29/22
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/10/22